The Assessment and Management of Antipsychotic-Associated Metabolic Disturbances from a Psychiatric Perspective

Canadian Journal of Psychiatry

Volumn 49, Issue 3, 2004, Pages 200-207

  Chue, Pierre ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b Community Living Program ^*  (Canada)

Author keywords

Atypical antipsychotics; Diabetes; Dyslipidemia; Weight gain

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BIGUANIDE DERIVATIVE; CAPTOPRIL; CLOZAPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; LOSARTAN; MEGLITINIDE; METFORMIN; NATEGLINIDE; NEUROLEPTIC AGENT; OLANZAPINE; ORAL ANTIDIABETIC AGENT; QUETIAPINE; RAMIPRIL; REPAGLINIDE; ROSIGLITAZONE; SERTINDOLE; SIBUTRAMINE; SULFONYLUREA DERIVATIVE; TETRAHYDROLIPSTATIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; ZOTEPINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES CONTROL; DIABETES MELLITUS; DIET THERAPY; DISEASE EXACERBATION; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG UTILIZATION; DYSLIPIDEMIA; EARLY DIAGNOSIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK POPULATION; HUMAN; HYPERTRIGLYCERIDEMIA; KINESIOTHERAPY; LIFESTYLE; MEDICAL LITERATURE; MEDICAL SPECIALIST; MENTAL DISEASE; MENTAL PATIENT; METABOLIC DISORDER; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OUTCOMES RESEARCH; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT REFERRAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

EID: 1942537067     PISSN: 07067437     EISSN: None     Source Type: Journal    
DOI: 10.1177/070674370404900308     Document Type: Review

References (111)

1. Wilon DR, D'Souza L, Sarkar N, Newton M. New-onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2003;59:1-6.
2. Seryak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck RA. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-6.
3. Gianfancesco FD, Grogg AL, Mahmoud RA, Ruey-hua Wang MS, Nasrallah HA. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry 2002;63:920-30.
4. Koro CE, Fedder DO, L'Italien GJ, Wiess SS, Magder LS, Kreyenbuhl, Revicki DA, Buchanan RW. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243-8.
5. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-45.
6. Wirhing DA, Spellberg BJ, Erhart SM, Marder SR. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-83.
7. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11:25-32.
8. Mir S, Taylor D. Atypical antipsychotics and hyperglycemia. Int Clin Psychopharmacol 2001;16:63-73.
9. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64.
10. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001;62:7-10.
11. Casey DE. Atypical antipsychotics: enhancing healthy outcomes. Arch Psychiatr Nurs 2002;3:S12-S19.
12. Baptista T. Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand 1999;100:3-16.
13. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62:22-31.
14. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs 2001;15:537-51.
15. Blin O, Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001;62:11-21.
16. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-96.
17. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, Mintz J, Marder SR. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.
18. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62:5-12.
19. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001;24:59-73.
20. Wetterling T, Müßigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999;19:316-21.
21. Taylor DM, McAskill R. Atypical antipsychotics and weight gain - a systematic review. Acta Psychiatr Scand 2000;101:416-32.
22. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62:40-1.
23. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. American Journal of Health-System Pharmacy 1996;53:2079-81.
24. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999;156:1270-2.
25. Su T-P, Elman I, Malhotra AK, Adler CM, Pickar D, Breier AF. Comparison of weight gain during risperidone and clozapine treatment in chronic schizophrenia. Presented at 149th Annual Meeting of the American Psychiatric Association; May 4-9, 1996; New York.
26. Bouchard RH, Demers MF, Simoneau I, Almeras N, Villeneuve J, Mottard JP, and others. Atypical antipsychotics and cardiovascular risk in schizophrenic patients. J Clin Psychopharmacol 2001;2110-1.
27. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry 1999;156:1471-2.
28. Osser DN, Najarian DM, Dufresne RL. Olanzapine increase weight and serum triglycerides. J Clin Psychiatry 1999;60:767-70.
29. Procyshyn RC, Kennedy NB, Marriage S, Wasan KM. Plasma protein and lipoprotein distribution of clozapine. Am J Psychiatry 2001;158:949-51.
30. Curkendall SM, Jingping M, Jones JK, Glasser D. Increased cardiovascular disease in patients with schizophrenia. Presented at the 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans (LA).
31. Goodman LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999;60:10-5.
32. Dixon L, Postrado L, Delahanty J, Fischer PJ, Lehman A. The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Mental Dis 1999;187:496-502.
33. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, Yale JF, Zinman B, Lillie D. 1998 clinical practice guidelines for the management of diabetes in Canada. CMAJ 1998;159:S1-S29.
34. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27:S1-S152.
35. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003;160:284-9.
36. Regenold W, Thapar R, Marano C, Gavirneni S, Kondapavuluru P. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70:19-26.
37. Wolever T. Dietary carbohydrates in the insulin resistance syndrome. Can J CME 2001;13(11):121-35.
38. Reinstein MJ, Sirotovkaya LA, Jones LE, Mohan S, Chasanov MA. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999;18:99-104.
39. Alberti KG. Impaired glucose tolerance: what are the clinical implications? Diabetes Res Clin Pract 1998;40(Suppl):S3-S8.
40. Tominga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Fungata diabetes study. Diabetes Care 1999;22:920-4.
41. Granberry MC, Fonseca VA. Insulin resistance syndrome: options for treatment. South Med J 1999;92:2-14.
42. Bonner G. Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol 1994;24(Suppl):S39-S49.
43. Tuomilheto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, and others. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
44. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;344:1343-50.
45. Chiasson JL, Josse RG, Gomis R, Hanefield M, Karasik A, Laakso M, for the STOP-NINDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;359:2072-7.
46. Smith SA, Lister CA, Toseland CD, Buckingham RE. Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab 2000;2:363-72.
47. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000;255:253-9.
48. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, and others. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879-86.
49. Scheen AJ. Prevention of type II diabetes by inhibiting the rennin-angiotensin system. Rev Med Liege 2002;57:449-52.
50. Scheen AJ. Prevention of type 2 diabetes in obese patients: first results with orlistat in the Xendos study. Rev Med Liege 2002;57:617-21.
51. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, and others. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55.
52. Halle J-P. The management and treatment of type 2 diabetes. Can J CME 2001;13(6):65-77.
53. QuED Study Group. The relationship between physicians' self-reported target fasting blood glucose levels and metabolic control in type 2 diabetes. Diabetes Care 2001;24:423-9.
54. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). BMJ 1998;352:854-65.
55. Awartani KA, Cheung AP. Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynaecol Can 2002;24:393-401.
56. Linne Y, Barkeling B, Rossner S. Natural course of gestational diabetes mellitus: long term follow up of women in the SPAWN study. Br J Obstet Gynaecol 2002;109:1227-31.
57. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998;49:997.
58. Littrell KH, Johnson CG, Peabody CD, Hilligoss N. Antipsychotics during pregnancy. Am J Psychiatry 2000;157:1342.
59. Cohn TA, Cheung R, Curnew R. Medical assessment of the patient (MAP) on antipsychotic treatment. Toronto: CTC Communications; 2000. p 1-27.
60. Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, and others. 1999 Canadian recommendations for the management of hypertension. CMAJ 1999;161(Suppl):S1-S17.
61. Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001;62:13-22.
62. Koren G. Maternal obesity and risk of neural tube defects. Can Fam Physician 2002;47:1385-7.
63. Canadian Task Force on Development of the Healthy Heart Kit. The healthy heart kit: helping your patients reduce their risk. Ottawa: Health Canada; 1999.
64. Daniel M, Rowley KG, McDermott R, O'Dea K. Diabetes and impaired glucose tolerance in Aboriginal Australians: prevalence and risk. Diabetes Res Clin Pract 2002;57:23-33.
65. Kurtzhaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62:32-7.
66. Jones B, Basson BR, Walker DJ, Crawford AM, Kinon BJ. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry 2001;62:41-4.
67. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-81.
68. Werneke U, Taylor D, Saunders TA. Options for the pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol 2002;17:145-60.
69. Aquila R. Management of weight gain in patients with schizophrenia. J Clin Psychiatry 2002;63:33-6.
70. Le Fevre PD. Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism? Scott Med J 2001;46:11-3.
71. Daniel DG, Weiden PJ, O'Sullivan R. Improvement in indices of health status in outpatients with schizophrenia following a switch to ziprasidone from conventional antipsychotics, olanzapine or risperidone. Presented at 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans (LA).
72. Berry S, Mahmoud R. Improvement of insulin indices after switch from olanzapine to risperidone. Presented at the 15th Congress of the European College of Neuropsychopharmacology; October 5-9, 2002; Barcelona (Spain).
73. Isojarvi JL, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-8.
74. McIntyre RS, Mancini DA, McMann S, Srinivasan J, Kennedy SHE. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disorders J. Forthcoming.
75. Cheskin LJ, Bartlett SJ, Zayaz R, Twilley CH, Allison DB, Contoreggi C. Prescription medications: a modifiable contributor to obesity. South Med J 1999;92:898-904.
76. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. Bethesda (MD): National Institutes of Health; June 1998.
77. Baum A, Posluszny DM. Health psychology: mapping biobehavioral contributions to health and illness. Annu Rev Psychol 1999;50:137-63.
78. Virkkunen M, Wahlbeck K, Rissanen A, Naukkarinen H, Franssila-Kallunki A. Decrease of energy expenditure causes weight increase in olanzapine treatment - a case study. Pharmacopsychiatry 2002;35:124-6.
79. Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000;22:224-35.
80. Cohn T, Remington G. Changing times, changing concerns a cross sectional study of antipsychotic medication use and cardiac risk factors in 213 long-term psychiatric in-patients. Int J Neuropsychopharmacol 2000;3(Suppl):S153.
81. Ball MP, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. Psychiatr Serv 2001;52:967-9.
82. Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Educational interventions for the management of antipsychotic-related weight gain. Presented at 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans (LA).
83. Nguyen CT, Ortiz, Franklin D, Maguire G. Nutritional education in minimizing weight gain associated with antipsychotic therapy. Presented at 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans (LA).
84. O'Keefe C, Noordsy D, Liss T, et al. Reversal of weight gain with antipsychotic treatment. Presented at 41st Annual Meeting of the New Clinical Drug Evaluation Unit; May 28-31, 2001; Phoenix (AZ).
85. Umbricht D, Flury H, Bridler R. Cognitive behavior therapy for weight gain. Am J Psychiatry 2001;158:971.
86. Frankenburg RF, Zanarini MC, Kando J, Centorrino F. Clozapine and body mass change. Biol Psychiatry 1998;43:520-4.
87. Gharabawi G, Mao L, Mahmoud R, Lasser R. Smoking status and olanzapine-induced weight gain: counter-intuitive findings. Presented at XIth Biennial Winter Workshop on Schizophrenia; February 24-March 1, 2002; Davos (Switzerland).
88. Ohlsen RJ, Jones HM, Ohlsen JC, Pilowsky LS. Antipsychotic induced weight gain: gender differences in response to intervention. Presented at XIth Biennial Winter Workshop on Schizophrenia; February 24-March 1, 2002; Davos (Switzerland).
89. Heimberg C, Gallacher F, Gur RC, Gur RE. Diet and gender moderate clozapine-related weight gain. Human Psychopharmacol 1995;10:367-71.
90. Wadden TA, Foster GD, Brownell KD. Obesity: responding to the global epidemic. J Consult Clin Psychol 2002;70:510-25.
91. Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophr Bull 1995;21:463-72.
92. Haller C, Schwartz JB. Pharmacologic agents for weight reduction. J Gend Specif Med 2002;5(5):16-21.
93. Anghelescu I, Klawe C, Benkert O. Orlistat in the treatment of psychopharmacologically induced weight gain. J Clin Psychopharmacol 2000;20:716-7.
94. Hilger E, Quiner S, Ginzel I, Walter H, Saria L, Barnas C. The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy. J Clin Psychopharmacol 2002;22:68-70.
95. Poyurovsky M, Pashnian A, Fuchs C, Gilad I, Maayan R, Weizman A. Olanzapine-induced weight gain in patients with first-episode schizophrenia. Presented at 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans (LA).
96. Breier AF, Tanaka Y, Roychowdhury S. Nizatidine ameliorates olanzapine associated weight gain in schizophrenia and related disorders-a randomized controlled double blind study. Presented at International Congress of Schizophrenia Research; April 28-May 2, 2001; Whistler (BC).
97. Sacchetti E, Guarneri L, Bravi D. H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry 2000;48:167-8.
98. Abuzzahab FS, Brown VL. Anorexogenic effects of topiramate in schizophrenia. Presented at the 154th Annual Meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans (LA).
99. Littrell KHZ. Weight loss with topiramate. Ann Pharmacother 2001;35;1141-2.
100. Kraus T, Zimmermann U, Schuid A, Haack M, Hinze-Selch D, Pollmacher T. The physiopathology of weight regulation during treatment with psychotropic drugs (Ger). Fortschr Neurol Psychiatr. 2001;69:116-37.
101. Kaur G, Kulkarni SK. Studies on modulation of feeding behaviour by atypical antipsychotics in female mice. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:277-85.
102. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacol 2001;11:181-2.
103. Baruch R, Poulin M, Thakur A, Karagianis J. Amantadine induces weight loss in patients treated with olanzapine. Presented at XIth Biennial Winter Workshop on Schizophrenia; February 24-March 1, 2002; Davos (Swizerland).
104. Cottingham EM. Metformin leads to weight loss in adolescents who gained weight on psychotropic drugs. Presented at the 153rd Annual Meeting of the American Psychiatric Association; May 13-18, 2000; Chicago (IL).
105. Depres JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ 2001;332:716-20.
106. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews 2002;23:201-29.
107. Fodor J, Frolich J, Genest J, McPherson R, for the Working Group on Hypercholesteremia and other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia. CMAJ 2000;162:1441-7.
108. Wooltorton E. Bayer pulls ceristatin (Baycol) from market. CMAJ 2001;165:632.
109. Fung MA, Frohlich JJ. Common problems in the management of hypertriglyceridemia. CMAJ 2002;167:1261-6.
110. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 2001;101:277-88.
111. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002;63:856-65.